A review of the drug−drug interactions of the antiepileptic drug brivaracetam

Moseley, Brian D.; Chanteux, Hugues; Nicolas, Jean‐Marie; Laloyaux, Cédric; Gidal, Barry E.; Stockis, Armel

doi:10.1016/j.eplepsyres.2020.106327

Cited by 43 publications

(40 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Levetiracetam is a broad-spectrum antiepileptic drug with a unique mechanism of action. AEDs are strong agents that can cause numerous adverse reactions and drug-drug interactions [13][14][15]. This survey is aimed to determine the usage, availability and knowledge of toxicity of Levetiracetam among the patients.…”

Section: Discussionmentioning

confidence: 99%

Levetiracetam Use, Availability and Knowledge of Toxicity Among Epileptic Patients and Their Care Givers: A Cross-Sectional Study in King Salman Armed Forces Hospital Tabuk Saudi Arabia

Alatawi

Alzahrani

Saiyed

2021

ijsr

View full text Add to dashboard Cite

Background: Levetiracetam (Keppra®) is a well-known second-generation anti-epileptic drug (AED). The study was aimed to addresses Levetiracetam use, availability and knowledge of toxicity among epileptic patients and their care givers in King Salman Armed Forces Hospital Tabuk Saudi Arabia. Methods: This cross-sectional survey was conducted in King Salman Armed Forces Hospital (KSAFH) in Tabuk city in Saudi Arabia. The study participants were epileptic patients and their care givers, selected from different outpatient departments using a convenient sampling technique. Data was collected using an Arabic self-reported questionnaire consisted of open-ended and closed-ended questions to facilitate study participants. Altogether, 381 persons answered the full questionnaire. The data were entered into SPSS version 26.0 for Windows, cleaned and managed before analysis. Results: Participants age ranged from 18 to 63 years, with a mean 29.6 years and standard deviation 5.8 years. 47.0% (n= 179) were male and 53.0% (n= 202) female. Six out of ten participants lived in the urban area (67.7%). Majority of the participants had knowledge about seizures (96.9%). About 31.0% of the participants and/or patients had seizures (epilepsy) since more than 20 years. Nearly 28.0% participants and/or patients had family history of seizures (epilepsy). Majority of the participants had Levetiracetam at home and aware of the correct usage of it. However, about 11% of the participants felt that Levetiracetam is used to help sleep. Eight out of ten of the participants reported “Sleepiness” as the side effect of Levetiracetam (79.3%). Half of the participants reported “Headache” as the side effect of Levetiracetam. About 94.0% of the participants knew that someone could take enough Levetiracetam to harm themselves. Conclusion: The study population used Levetiracetam, they demonstrated basic awareness of Levetiracetam use including the potential consequences of overdosing. Participants' knowledge regarding the toxicity of Levetiracetam is adequate. Special awareness programs for parents of children with epilepsy may be needed to reduce the knowledge gaps in the management of epilepsy and to ensure compliance and optimal therapeutic outcomes.

show abstract

Section: Discussionmentioning

confidence: 99%

Levetiracetam Use, Availability and Knowledge of Toxicity Among Epileptic Patients and Their Care Givers: A Cross-Sectional Study in King Salman Armed Forces Hospital Tabuk Saudi Arabia

Alatawi

Alzahrani

Saiyed

2021

ijsr

View full text Add to dashboard Cite

show abstract

“…Hladinu brivaracetamu snižuje karbamazepin, fenytoin, primidon (5). Rifampicin snižuje AUC o 45 % (5,9).…”

Section: Vliv Dalších Léků Na Brivaracetamunclassified

Drug interactions of antiepileptic drugs Part 2: interaction with drugs of other indication groups

Kořístková¹,

Grundmann²

2021

Klin Farmakol Farm

View full text Add to dashboard Cite

Na úrovni farmakokinetiky jsou lékové interakce antiepileptik spojeny obvykle s enzymatickou indukcí nebo inhibicí. Méně časté jsou interakce v oblasti absorpce, vazby na plazmatické bílkoviny nebo renální exkrece. Farmakodynamické interakce antiepileptik s dalšími látkami se zřídka týkají synergismu s možností snížení dávek, spíše se zvyšuje incidence vedlejších účinků. Čistě farmakodynamické interakce byly popsány u oxcarbazepinu, perampanelu a pregabalinu. Nová antiepileptika mají nižší interakční potenciál -řada z nich se vylučuje renálně nebo extrahepatálně (např. gabapentin, lacosamid, levetiracetam, topiramát, vigabatrin). K enzymatické indukci pak nedochází vůbec nebo zcela minimálně. Ze starších látek lze počítat s projevem indukčního efektu u karbamazepinu, fenytoinu a fenobarbitalu. Inhibiční efekt se uplatňuje u valproátu a felbamátu. Z nových látek je interakční potenciál nejvyšší u lamotriginu, oxcarbazepinu a rufinamidu. Lékové interakce nebyly popsány u lacosamidu, pregabalinu, stiripentolu a vigabatrinu.

show abstract

“…Therapeutic drug monitoring (TDM) is an important treatment aid in both patients and clinicians (Cheng et al, 2020;García-Ferrer et al, 2019). The individualization of drug dosages for patients enables plasma drug concentrations to be kept within a safe and effective range, which fundamentally solves the problem of the uncertainty of varying pharmacokinetic behavior (de Vries Schultink, Huitema, & Beijnen, 2018;Reis et al, 2018) and physicochemical properties of the drug (Barco et al, 2020;van Nuland et al, 2019), particularly in patients with severe liver and kidney impairment and drug-drug interaction (Moseley et al, 2020;Sridharan, Al Daylami, Ajjawi, & Al Ajooz, 2020). Therefore, TDM is of great significance for guiding individualized clinical treatment.…”

Section: Introductionmentioning

confidence: 99%

A UPLC–MS/MS method for simultaneous determination of nine antiepileptic drugs in human plasma and its application in TDM

Liu

2021

Biomedical Chromatography

View full text Add to dashboard Cite

With the purpose of carrying out therapeutic drug monitoring (TDM) of nine antiepileptic drugs simultaneously in the clinic, a UPLC-MS/MS assay method was developed and validated. Separation of antiepileptic drugs and internal standard (naproxen and diazepam) was performed on an Agilent Eclipse XDB-C 18 column (50.0 × 2.1 mm, 1.7 μm) using water and acetonitrile as mobile phase for gradient elution. Polarity switch ionization mode (positive-negative-positive) was performed in a total run time of 3.0 min. The method validation was conducted based on bioanalytical method validation guidance, including specificity, calibration curve, precision, accuracy, recovery, matrix effect, stability and dilution integrity, and all of the results satisfied the requirements. Consequently, the proposed method was applied to the TDM of nine antiepileptic drugs and was proved to be sensitive, reliable and specific to determine antiepileptic drugs in human plasma simultaneously.Meanwhile, the TDM results showed that the plasma drug concentration of many patients was not within the effective therapeutic range, especially those taking topiramate, oxcarbazepine and levetiracetam, which was of great guiding significance to rational drug use and timely adjustment of the treatment plan. Therefore, individualized therapy based on advanced analytical methods and TDM theory is of great practical significance.

show abstract

A review of the drug−drug interactions of the antiepileptic drug brivaracetam

Cited by 43 publications

References 55 publications

Levetiracetam Use, Availability and Knowledge of Toxicity Among Epileptic Patients and Their Care Givers: A Cross-Sectional Study in King Salman Armed Forces Hospital Tabuk Saudi Arabia

Levetiracetam Use, Availability and Knowledge of Toxicity Among Epileptic Patients and Their Care Givers: A Cross-Sectional Study in King Salman Armed Forces Hospital Tabuk Saudi Arabia

Drug interactions of antiepileptic drugs Part 2: interaction with drugs of other indication groups

A UPLC–MS/MS method for simultaneous determination of nine antiepileptic drugs in human plasma and its application in TDM

Contact Info

Product

Resources

About